Proof-of-concept data in cancer for Arrowhead Research Corp.'s peptide-based tissue targeting platform were good enough to get Shire plc on board to use the technology for rare diseases.

Last week, the companies partnered to use Arrowhead's Homing Peptide technology to discover peptide-drug conjugates. Arrowhead will identify peptides that selectively target an undisclosed tissue type, and Shire will provide the therapeutic payload.